Evidence map›Paper›PMID 38511104›Full record

ArticleCurrent therapeutic research, clinical and experimental2024

Comparison Between Moxifloxacin and Chloramphenicol for the Treatment of Bacterial Eye Infections.

Valentina Gentili, Giovanni Strazzabosco, Rossella Spena, Sabrina Rizzo, Silvia Beltrami, Giovanna Schiuma, Andrea Alogna, Roberta Rizzo

Open access · goldAbstract read
In one paragraph

Article in Current therapeutic research, clinical and experimental, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Fluoroquinolones and Biofilm: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Valentina GentiliDepartment of Chemical, Pharmaceutical, and Agricultural Science, University of Ferrara, Ferrara, Italy.
Giovanni StrazzaboscoDepartment of Chemical, Pharmaceutical, and Agricultural Science, University of Ferrara, Ferrara, Italy.
Rossella SpenaDepartment of Translational Medicine, University of Ferrara, Ferrara, Italy.
Sabrina RizzoDepartment of Chemical, Pharmaceutical, and Agricultural Science, University of Ferrara, Ferrara, Italy.
Silvia BeltramiDepartment of Chemical, Pharmaceutical, and Agricultural Science, University of Ferrara, Ferrara, Italy.
Giovanna SchiumaDepartment of Chemical, Pharmaceutical, and Agricultural Science, University of Ferrara, Ferrara, Italy.
Andrea AlognaDepartment of Chemical, Pharmaceutical, and Agricultural Science, University of Ferrara, Ferrara, Italy.
Roberta RizzoDepartment of Chemical, Pharmaceutical, and Agricultural Science, University of Ferrara, Ferrara, Italy.
University of Ferrara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Moxifloxacin is a bactericidal methoxyquinolone used for the treatment of conjunctivitis and prophylactic therapy in cataract and refractive surgeries. Chloramphenicol is a bacteriostatic organochlorine introduced into clinical practice in 1948 and used mainly in topical preparations because of its known toxicity. Objectives: The study aimed to evaluate the in vitro antibacterial effect and the ocular cytotoxicity of these broad-spectrum antibiotics. Methods: Antimicrobic activity was tested on 4 bacteria strains ( Results: Cytotoxicity of antibiotics was evaluated on human epithelial corneal cells after 4 hours treatment by viability assay. Results showed that corneal cell viability was significantly higher after moxifloxacin treatment compared with chloramphenicol ( Conclusions: The lower corneal cell toxicity and the broader spectrum of antibacterial activity observed with moxifloxacin suggests its use in ophthalmic solution for the treatment of bacterial eye infections.

Indexed as

Antibacterial activityAntibiofilmCytotoxicityProphylaxis

Identifiers

PMID38511104
PMCPMC10950741
OpenAlexW4392246863

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.